Skip to main content

Peer Review reports

From: Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC

Original Submission
11 Jul 2021 Submitted Original manuscript
29 Jul 2021 Reviewed Reviewer Report
31 Jul 2021 Reviewed Reviewer Report
1 Aug 2021 Reviewed Reviewer Report
29 Aug 2021 Author responded Author comments - Yongchang Zhang
Resubmission - Version 2
29 Aug 2021 Submitted Manuscript version 2
31 Aug 2021 Reviewed Reviewer Report
31 Aug 2021 Reviewed Reviewer Report
2 Sep 2021 Author responded Author comments - Yongchang Zhang
Resubmission - Version 3
2 Sep 2021 Submitted Manuscript version 3
Publishing
3 Sep 2021 Editorially accepted
19 Oct 2021 Article published 10.1186/s12916-021-02118-x

You can find further information about peer review here.

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us